Vaxcyte Launches Dual $500M Stock and Convertible Note Offerings
Vaxcyte is raising up to $1 billion through simultaneous public offerings of common stock and 2032 convertible senior notes.
Vaxcyte, Inc., a clinical-stage vaccine developer listed on Nasdaq under the ticker PCVX, announced Monday the commencement of two separate underwritten public offerings totaling $1 billion, comprising $500 million in common stock and pre-funded warrants alongside $500 million in convertible senior notes due 2032.
The San Carlos, California-based company is conducting both offerings under registrations filed with the Securities Act of 1933. Vaxcyte has also extended underwriters a 30-day option to purchase up to an additional $75 million in common shares and a separate $75 million in additional notes to cover any over-allotments, potentially pushing total proceeds above $1.15 billion if both options are fully exercised.
Read more Bavarian Nordic Discloses Share Buyback Activity Under DKK 250M Program →
The two offerings are structured independently of one another, meaning the completion of the equity offering carries no dependency on the closing of the notes offering, and vice versa. This structure gives the company flexibility to close one transaction even if market conditions prevent the other from proceeding.
As a clinical-stage company, Vaxcyte does not yet generate commercial revenue, making large capital raises a critical mechanism for funding ongoing vaccine research and development programs. The dual-tranche approach — combining equity with convertible debt — is a common strategy among pre-revenue biotechs seeking to balance dilution against balance-sheet flexibility. No pricing terms or final offering sizes have been disclosed, and the company cautioned that completion of either offering remains subject to market conditions with no guarantee of timing or final terms.
Continue reading at GlobeNewswire - Industry News on Financial Services.
